Journal articleFuture Oncol2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
- Journal
- Future Oncol
- Published
- 18 November 2022
- Citations
- 5
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Immune checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. … Excerpt only: this text is the publisher’s. Read it in full at the source.